mibampator
Small moleculeexperimental
Mibampator is a positive allosteric modulator (PAM) of the AMPA receptor (AMPAR), an ionotropic glutamate receptor, which was under development by Eli Lilly for the treatment of agitation/aggression in Alzheimer's disease but was never marketed. It reached phase II clinical trials prior to the discontinuation of its development. — Wikipedia
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2002 (NCT00051909)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Glutamate receptor ionotropic AMPAPOSITIVE ALLOSTERIC MODULATOR
Glutamate receptor ionotropic AMPA positive allosteric modulator
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)S(=O)(=O)NC[C@H](C)c1ccc(-c2ccc(CCNS(C)(=O)=O)cc2)cc1- Mol. weight
- 438.62 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMibampator ↗
- ChEMBLCHEMBL1277001 ↗
Also known as
- ly451395
- ly451395
- ly451395
- ly 451395
- ly-451395
- ly-451395
- ly-451395
- mibampator
- mibampator
- mibampator
- n-((2-(4'-(2-(methylsulfonyl)amino)ethyl)(1,1'-biphenyl)-4-yl)propyl)-2-propanesulfonamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00843518 | Phase 2 | Feb 1, 2009 | Eli Lilly |
| NCT00051909 | Phase 2 | Nov 1, 2002 | Eli Lilly |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 2 | 2 | 1 | 2002 |
1 organizations
Page 1 / 1